Drug Trial Radar · NCT07037758
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Sep 16, 2025
Primary completion
Mar 18, 2028
Study completion Jan 18, 2031
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- Asher Biotherapeutics, Inc.
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.
Conditions
- Extensive Stage Small Cell Lung Cancer
Interventions
TarlatamabDrug
Administered as an IV infusion.
AB248Drug
Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 2.5 years
- Dose Exploration: Number of Participants with Dose-limiting Toxicities (DLTs)Time frame: Up to 35 days
Locations
19 sites in 3 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Terminated
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Norton Cancer Institute - Downtown
Louisville, Kentucky · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Siteman Cancer Center
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania · Recruiting
Allegheny General Hospital
Pittsburgh, Pennsylvania · Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota · Recruiting
Baptist Cancer Center
Memphis, Tennessee · Recruiting
Swedish Cancer Institute Medical Oncology
Seattle, Washington · Recruiting
Chungbuk National University Hospital
Cheongju Chungbuk, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Severance Hospital Yonsei University Health System
Seoul, South Korea · Recruiting
Adana Sehir Egitim ve Arastirma Hastanesi
Adana, Turkey (Türkiye) · Recruiting
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, Turkey (Türkiye) · Recruiting
Ankara Bilkent Sehir Hastanesi
Ankara, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.